ABOUT US VAMOROLONE CLINICAL TRIALS RESEARCH NEWS CONTACT ReveraGen BioPharma News News ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

<span>ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone , a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy</span>

ReveraGen BioPharma, Inc. today announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy. More >

Source: www.reveragen.com